Trial Profile
Phase 3 Multicenter Randomized Trial to Evaluate Efficacy and Safety of CPI-613 in Combination With HD Cyt. and Mito. vs HD Cyt. and Mito. Therapy and Control Sub-groups in Older Patients With R/R AML
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 16 Jan 2023
Price :
$35
*
At a glance
- Drugs Devimistat (Primary) ; Cytarabine; Etoposide; Filgrastim; Fludarabine; Mitoxantrone
- Indications Acute myeloid leukaemia
- Focus Registrational; Therapeutic Use
- Acronyms ARMADA 2000
- Sponsors Cornerstone Pharmaceuticals Inc
- 01 Jan 2023 This trial has been discontinued in Italy, according to European Clinical Trials Database record.
- 20 Aug 2022 This trial has been completed in Germany (Date of the global end of the trial : 28-Oct-2021), according to European Clinical Trials Database record.
- 19 Nov 2021 This trial has been completed in Belgium, according to European Clinical Trials Database record.